BioGaia AB (publ) (LON:0GTN)

Market Cap	849.51M
Revenue (ttm)	115.46M
Net Income (ttm)	24.94M
Shares Out	n/a
EPS (ttm)	0.25
PE Ratio	34.06
Forward PE	27.30
Dividend	0.54 (0.51%)
Ex-Dividend Date	May 8, 2025

Volume	218,067
Average Volume	17,845
Open	105.30
Previous Close	105.40
Day's Range	105.20 - 106.20
52-Week Range	93.60 - 134.60
Beta	0.66
RSI	64.58
Earnings Date	Oct 21, 2025

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablet...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 225
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GTN

Financial Performance

In 2024, BioGaia AB's revenue was 1.42 billion, an increase of 9.73% compared to the previous year's 1.30 billion. Earnings were 351.39 million, a decrease of -3.82%.

Financial numbers in SEK